J Clin Invest. 2018 Feb 1;128(2):567-569. doi: 10.1172/JCI99037. Epub 2018 Jan 16.
Hepatic glucose production (HGP) is a key determinant of glucose homeostasis. Glucagon binding to its cognate seven-transmembrane Gs-coupled receptor in hepatocytes stimulates cAMP production, resulting in increased HGP. In this issue of the JCI, Rossi and colleagues tested the hypothesis that activation of hepatic Gi-coupled receptors, which should inhibit cAMP production, would oppose the cAMP-inducing action of glucagon and thereby decrease HGP. Surprisingly, however, the opposite occurred: activation of Gi signaling increased HGP via a novel mechanism, while inhibition of Gi signaling reduced HGP. These results define a new physiologic role for hepatic Gi signaling and identify a potential therapeutic target for HGP regulation.
肝脏葡萄糖生成 (HGP) 是葡萄糖稳态的关键决定因素。胰高血糖素与肝细胞中同源的七跨膜 Gs 偶联受体结合,刺激 cAMP 的产生,从而增加 HGP。在本期 JCI 中,Rossi 及其同事检验了这样一个假设,即激活肝 Gi 偶联受体(应该会抑制 cAMP 的产生)会拮抗胰高血糖素诱导 cAMP 的作用,从而降低 HGP。然而,令人惊讶的是,实际情况正好相反:Gi 信号的激活通过一种新的机制增加了 HGP,而 Gi 信号的抑制则降低了 HGP。这些结果定义了肝 Gi 信号的新的生理作用,并确定了 HGP 调节的一个潜在治疗靶点。